摘要
目的:探讨替米沙坦联合氢氯噻嗪治疗轻中度高血压的临床疗效。方法:选取2015年1月-2017年4月本院收治的82例轻中度高血压患者,采用随机数字表法分为对照组和观察组,每组41例。对照组采用氢氯噻嗪治疗,观察组采用替米沙坦联合氢氯噻嗪治疗,观察两组降压效果、血钾、血尿酸指标变化和不良反应情况。结果:治疗2、4、6周后,观察组SBP和DBP指标水平[(141.24±10.35)、(131.02±10.03)、(128.35±8.02)mm Hg,(111.24±11.34)、(90.25±10.24)、(84.96±6.57)mm Hg]均低于对照组[(149.24±11.02)、(139.57±11.23)、(136.98±9.47)mm Hg,(120.14±8.17)、(108.24±12.04)、(91.47±5.24)mm Hg],差异均有统计学意义(P<0.05)。观察组治疗总有效率(95.12%)高于对照组(78.05%),差异有统计学意义(P<0.05)。治疗后,观察组血钾(4.33±1.02)mmol/L、血尿酸(344.64±52.03)μmol/L水平与对照组[(4.25±1.34)mmol/L、(348.57±49.71)μmol/L]比较,差异均无统计学意义(P>0.05),且两组血钾、血尿酸指标水平均与治疗前比较,差异均无统计学意义(P>0.05)。观察组不良反应发生率(17.07%)略高于对照组(12.20%),但差异无统计学意义(P>0.05)。结论:替米沙坦联合氢氯噻嗪治疗轻中度高血压临床疗效可靠。
Objective： To investigate the clinical efficacy of Telmisartan Combined with Hydrochlorothiazide in the treatment of mild to moderate hypertension.Method： From January 2015 to April 2017, 82 patients with mild and moderate hypertension treated in our hospital were selected and divided into the control group and the observation group according to the random number table method, 41 cases in each group.The control group was treated With Hydrochlorothiazide, the observation group was treated with Telmisartan combined with Hydroehlorothiazide, the antihypertensive effect of two groups were observed, and the changes of blood potassium, serum uric acid and adverse reactions of two groups were observed,Result： Mter treated 2, 4 and 6 weeks, SBP and DBP[ （ 141.24 ± 10.35 ）, （ 131.02 ± 10.03 ）, （ 128.35 ±1,02 ）, （ 111,24 ± 11,34 ）, （ 90.25 ± 10.24 ）, （84.96 ± 6.57 ） mm Hal of the observation group were lower than those of the control group[ （ 149.24 ± 11.02 ）, （ 139.57 ± 11.23 ）, （ 136.98 ± 9.47 ）, （ 120.14 ± 8.17 ）, （ 108,24 ± 12.04 ）, （ 91.47 ± 5.24 ）mm Hal, the differences were statistically significant （ P〈0.05 ） .The total effective rate of the observation group （ 95.12% ） was higher than that of the control group （ 78.05% ）, the difference was statistic significant （ P〈0.05 ） .After treatment, there were no significant differences between blood potassium[ （4.33 ± 1.02 ） mmol/L], blood uric acid[ （ 344.64 ± 52.03 ） μ mol/L]levels of the observation group were similar to those of the control group[ （ 4.25 ± 1.34 ） mmol/L, （ 348.57 ± 49.71 ） μmol/L] （ P〉0.05 ）, and the serum potassium, serum uric acid level before and after treatment of two groups were no significant differences （ P〉0.05 ） ,The adverse reactions incidence of the observation group （ 17.07% ） was slightly higher than that of the control group （ 12.20% ）, but there was no significant difference （P〉0.05） .Conclusion： The clinical efficacy of Telmisartan eombined with Hvdroehlorothiazide in the treatment of mild to moderate hvoertension is reliable.
作者
卢智胜
刘武定
LU Zhi-sheng LIU Wu-ding(Zhongshan Chen Xinghai Hospital, Zhongshan 525415, China)
出处
《中国医学创新》
CAS
2017年第23期127-130,共4页
Medical Innovation of China
关键词
替米沙坦
氢氯噻嗪
轻中度高血压
临床疗效
Telmisartan
Hydrochlorothiazide
Mild to moderate hypertension
Clinical efficacy
